Journal
JOURNAL OF MOLECULAR NEUROSCIENCE
Volume 20, Issue 3, Pages 327-337Publisher
HUMANA PRESS INC
DOI: 10.1385/JMN:20:3:327
Keywords
apolipoprotein E; Alzheimer's disease; protease inhibitors; proteolysis; therapeutics; drug design
Categories
Funding
- NINDS NIH HHS [R43 NS43092] Funding Source: Medline
Ask authors/readers for more resources
Apolipoprotein E (apoE) remains the most important genetic risk factor for the development of Alzheimer's disease (AD). Still elusive, the role of apoE is under intense investigation. We propose that proteolysis of apoE in the brain leads to two major fragments, N- and C-terminal apoE, each of which would drive a different neuropathological pathway. N-terminal fragments of apoE are implicated in neurotoxicity, and C-terminal fragments might play a role in amyloid deposition and plaque formation. The greater risk of AD associated with the E4 isoform might relate to its greater neurotoxicity. Drugs that either directly inhibit the toxic effects of apoE or prevent the production of apoE fragments may provide novel therapeutic approaches to the treatment of AD and other disorders in which apoE is implicated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available